The management of non-small cell lung cancer has undergone major transformation in the last three years driven by the increasing using of immunotherapy as well as local ablative therapies in advanced stage disease. Translation of these practices into community based setting is important as overall survival in lung cancer has dramatically improved with incorporation of improved treatment. This educational activity will help participants to better apply new treatment strategies so that patient outcomes can be enhanced.
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Apply the increasing role of radiotherapy in advance stage lung cancer.
- Describe the instances when radiotherapy for advanced stage disease is not indicated.
Russell Hales, MD is employed by Johns Hopkins University and has no financial relationships with a commercial interest.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.